{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T17:43:02Z","timestamp":1783618982556,"version":"3.55.0"},"reference-count":17,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T00:00:00Z","timestamp":1680739200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"European Union\u2019s Horizon 2020 Research and Innovation Programme","award":["777204"],"award-info":[{"award-number":["777204"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: Although disopyramide has been widely used to reduce left ventricular outflow obstruction (LVOTO) and to improve symptoms in patients with obstructive hypertrophic cardiomyopathy (oHCM), its use in real world as well as patient characteristics associated with a positive treatment response are still unclear. Methods: From 1980 to 2021, 1527 patients with HCM were evaluated and 372 (23%) had a LVOTO with active follow-up. The efficacy and safety of disopyramide were assessed systematically during 12 months (2-, 6-, and 12-month visits). Responders were patients with a final NYHA = I and a LVOTO &lt; 30 mmHg; incomplete responders were those patients with NYHA &gt; I and a LVOTO &lt; 30 mmHg; and non-responders were symptomatic patients with no change in functional class NYHA and a LVOT gradient &gt; 30 mmHg. Results: Two-hundred-fifty-four (66%) patients were in functional class NYHA I\/II and 118 (34%) in NYHA III\/IV. A total of 118\/372 (32%, 55 \u00b1 16 years) underwent disopyramide therapy. Twenty-eight (24%) patients responded to therapy, 39 (33%) were incomplete responders, and 51 (43%) did not respond. Responder were mainly patients in functional NYHA class I\/II (24\/28, 86%), whereas incomplete responders and non-responders were more often in functional NYHA class III\/IV (50\/54 (93%)). An independent predictor of response to disopyramide treatment was the presence of NYHA I\/II at the initiation of therapy (HR 1.5 (95% CI 1.1\u20134.5), p = 0.03). No major life-threatening arrhythmic events or syncope occurred, despite 19 (16%) patients showing reduced QTc from baseline, 19 (16%) having no difference, while 80 (69%) patients had prolonged QTc interval. Thirty-one (26%) patients experienced side effects, in particular, 29 of the anticholinergic type. Conclusions: Disopyramide was underused in oHCM but effective in reducing LVOTO gradients and symptoms in slightly symptomatic patients with less severe disease phenotype with a safe pro-arrhythmic profile.<\/jats:p>","DOI":"10.3390\/jcm12072725","type":"journal-article","created":{"date-parts":[[2023,4,6]],"date-time":"2023-04-06T01:10:27Z","timestamp":1680743427000},"page":"2725","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Real-World Use and Predictors of Response to Disopyramide in Patients with Obstructive Hypertrophic Cardiomyopathy"],"prefix":"10.3390","volume":"12","author":[{"given":"Niccol\u00f2","family":"Maurizi","sequence":"first","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Florence, 50121 Florence, Italy"},{"name":"Service of Cardiology, University Hospital of Lausanne, 1009 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Chiriatti","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Fumagalli","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Targetti","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1920-2417","authenticated-orcid":false,"given":"Silvia","family":"Passantino","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8466-7360","authenticated-orcid":false,"given":"Panagiotis","family":"Antiochos","sequence":"additional","affiliation":[{"name":"Service of Cardiology, University Hospital of Lausanne, 1009 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ioannis","family":"Skalidis","sequence":"additional","affiliation":[{"name":"Service of Cardiology, University Hospital of Lausanne, 1009 Lausanne, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Chiti","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Biagioni","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessia","family":"Tomberli","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Giovani","sequence":"additional","affiliation":[{"name":"Cardiomyopathy Unit, Careggi University Hospital, 50134 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4096-3173","authenticated-orcid":false,"given":"Raffaele","family":"Coppini","sequence":"additional","affiliation":[{"name":"Department NeuroFarBa, University of Florence, 50121 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Cecchi","sequence":"additional","affiliation":[{"name":"Fondazione AICARM, 50100 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1751-9266","authenticated-orcid":false,"given":"Iacopo","family":"Olivotto","sequence":"additional","affiliation":[{"name":"Department of Clinical and Experimental Medicine, University of Florence, 50121 Florence, Italy"},{"name":"Service of Cardiology, Meyer Children\u2019s Hospital IRCCS, 50139 Florence, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,4,6]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1056\/NEJMra1710575","article-title":"Clinical course and management of hypertrophic cardiomyopathy","volume":"379","author":"Maron","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_2","unstructured":"Maurizi, N., Olivotto, I., Maron, M.S., Bonacchi, G., Antiochos, P., Tomberli, B., Fumagalli, C., Poggesi, C., Berteotti, M., and Girolami, F. (2023). Lifetime Clinical Course of Hypertrophic Cardiomyopathy: Outcome of the Historical Florence Cohort over Five Decades. JACC Adv., in press."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1161\/CIRCULATIONAHA.106.644682","article-title":"Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction","volume":"114","author":"Maron","year":"2006","journal-title":"Circulation"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.hfc.2018.01.001","article-title":"Clinical and Molecular Aspects of Cardiomyopathies: Emerging Therapies and Clinical Trials","volume":"14","author":"Maurizi","year":"2018","journal-title":"Heart Fail. Clin."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.1093\/eurheartj\/ehu284","article-title":"Authors\/Task Force members. 2014 ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: The Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC)","volume":"35","author":"Elliott","year":"2014","journal-title":"Eur. Heart J."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jacc.2005.01.012","article-title":"Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy","volume":"45","author":"Sherrid","year":"2005","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1161\/CIRCHEARTFAILURE.112.000122","article-title":"Treatment of obstructive hypertrophic cardiomyopathy symptoms and gradient resistant to first-line therapy with beta-blockade or verapamil","volume":"6","author":"Sherrid","year":"2013","journal-title":"Circ. Heart Fail."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.ijcard.2019.09.066","article-title":"Markers of responsiveness to disopyramide in patients with hypertrophic cardiomyopathy","volume":"297","author":"Habib","year":"2019","journal-title":"Int. J. Cardiol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"e005152","DOI":"10.1161\/JAHA.116.005152","article-title":"Safety of Outpatient Initiation of Disopyramide for Obstructive Hypertrophic Cardiomyopathy Patients","volume":"6","author":"Adler","year":"2017","journal-title":"J. Am. Heart Assoc."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e024656","DOI":"10.1161\/JAHA.121.024656","article-title":"Cardiac Myosin Inhibitors as a Novel Treatment Option for Obstructive Hypertrophic Cardiomyopathy: Addressing the Core of the Matter","volume":"11","author":"Masri","year":"2022","journal-title":"J. Am. Heart Assoc."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jacbts.2019.06.004","article-title":"Electrophysiological and Contractile Effects of Disopyramide in Patients With Obstructive Hypertrophic Cardiomyopathy: A Translational Study","volume":"4","author":"Coppini","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1007\/s11886-021-01508-0","article-title":"Mavacamten, a Novel Therapeutic Strategy for Obstructive Hypertrophic Cardiomyopathy","volume":"23","author":"Zampieri","year":"2021","journal-title":"Curr. Cardiol. Rep."},{"key":"ref_13","first-page":"e533","article-title":"2020 AHA\/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy: Executive Summary: A Report of the American College of Cardiology\/American Heart Association Joint Committee on Clinical Practice Guidelines","volume":"142","author":"Ommen","year":"2020","journal-title":"Circulation"},{"key":"ref_14","first-page":"33","article-title":"The contribution of Na channel block to the negative inotropic effect of antiarrhythmic drugs","volume":"81","year":"1986","journal-title":"Basic Res. Cardiol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0140-6736(20)32384-9","article-title":"Mavacamten for hypertrophic obstructive cardiomyopathy","volume":"397","author":"Quintana","year":"2021","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jamacardio.2019.5233","article-title":"Tafamidis\u2014A Pricey Therapy for a Not-So-Rare Condition","volume":"5","author":"Gurwitz","year":"2020","journal-title":"JAMA Cardiol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/S0140-6736(20)31792-X","article-title":"Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): A randomised, double-blind, placebo-controlled, phase 3 trial; EXPLORER-HCM study investigators","volume":"396","author":"Olivotto","year":"2020","journal-title":"Lancet"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/7\/2725\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:10:46Z","timestamp":1760123446000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/12\/7\/2725"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,6]]},"references-count":17,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["jcm12072725"],"URL":"https:\/\/doi.org\/10.3390\/jcm12072725","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,6]]}}}